Document Detail

Persistence of rickettsiae in the partially viable gangrenous margins of amputated extremities 5 to 7 weeks after onset of Rocky Mountain spotted fever.
MedLine Citation:
PMID:  7748070     Owner:  NLM     Status:  MEDLINE    
A case of Rocky Mountain spotted fever complicated by gangrene of the extremities required amputation and showed persistent rickettsial infection in the margins of the gangrene at 5 and 7 weeks after onset of illness. Rickettsial organisms were demonstrated by immunoperoxidase staining in the viable endothelial cells in the ischemic margins of the gangrenous tissue. We conclude that the cellular, humoral, and pharmacologic components that lead to eradication of the rickettsiae were not delivered to the ischemic margins at effective antirickettsial concentrations.
M G Hove; D H Walker
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Archives of pathology & laboratory medicine     Volume:  119     ISSN:  0003-9985     ISO Abbreviation:  Arch. Pathol. Lab. Med.     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-06-15     Completed Date:  1995-06-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7607091     Medline TA:  Arch Pathol Lab Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  429-31     Citation Subset:  AIM; IM    
Department of Pathology, University of Texas Medical Branch, Galveston 77555-0609, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fluorescent Antibody Technique
Gangrene / microbiology*,  surgery
Immunoenzyme Techniques
Rickettsia rickettsii / isolation & purification*
Rocky Mountain Spotted Fever / complications*,  microbiology*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The presence of Enterocytozoon bieneusi spores in the lamina propria of small bowel biopsies with no...
Next Document:  Expression of class II major histocompatibility complex antigens (HLA-DR) and lymphocyte subset immu...